Table 1.
Clinical characteristics (n = 117)
| Age, y | 64.0 ± 10.3 |
|---|---|
| Male (%) | 105 (89.7) |
| Medical history | |
| Hypertension (%) | 74 (63.2) |
| Diabetes (%) | 34 (29.1) |
| Hyperlipidemia (%) | 16 (13.7) |
| Smoking (%) | 32 (27.4) |
| Prior PCI (%) | 46 (39.3) |
| Prior CABG (%) | 9 (7.7) |
| Myocardial infarction history (%) | 24 (20.5) |
| Clinical manifestation | |
| Stable angina (%) | 98 (83.8) |
| Acute coronary syndrome (%) | 19 (16.2) |
| LVEF (%) | 60.8 ± 6.6 |
| Antithrombotic therapy during intervention | |
| Heparin (%) | 113 (96.6) |
| Bivalirudin (%) | 4 (3.4) |
| Glycoprotein IIb/IIIa inhibitor (%) | 14 (12.0) |
| Discharge medications | |
| Aspirin (%) | 105 (89.7) |
| Cilostazol (%) | 12 (10.3) |
| Clopidogrel (%) | 82 (70.1) |
| Ticagrelor (%) | 35 (29.9) |
| Beta blocker (%) | 90 (76.9) |
| RAS inhibitors (%) | 76 (65.0) |
| Statin (%) | 117 (100.0) |
| Ezetimibe (%) | 12 (10.3) |
Data are presented as mean ± SD or n (%)
PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction; RAS inhibitors, renin-angiotensin-system inhibitors